title: Clinical study on antithrombotic effects of ticlopidine in ischemic stroke.
abstract: The investigators conducted a clinical study on antithrombotic effectiveness in ischemic stroke at Siriraj Hospital Medical School, Mahidol University from May 1987 to May 1989. Twenty-nine patients, 16 males and 13 females were enrolled in the study. The ages of the patients ranged from 30-87 years with a mean age of 63 +/- 11 years. Ticlopidine (250 mg) could significantly inhibit platelet aggregation induced by ADP and collagen within 24 hours of drug administration. After 1 week to 6 months, only aggregation by ADP was still inhibited significantly without significant effects on fibrinolytic activity and prostacyclin. Hematocrit was significantly decreased at the 1st and 2nd month of treatment. Serious side effects were skin rash and severe headache while the other common ones were dizziness, and diarrhea but these effects disappeared without discontinuing the drug. Most patients who suffered from nausea, diarrhea and headache, had temporary elevated SGPT. It may be concluded that only half of the recommended dose of ticlopidine has inhibitory effects on both phases of ADP-induced aggregation without interfering with fibrinolytic activity and can maintain prostacyclin. However, it also possesses either serious or common side-effects. This drug, therefore, should be used with the awareness of the clinician.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: K
authors.initials: K
authors.lastname: Ketsa-Ard
authors.forename: N
authors.initials: N
authors.lastname: Poungvarin
authors.forename: M
authors.initials: M
authors.lastname: Juengchareon
authors.forename: S
authors.initials: S
authors.lastname: Jarerat
authors.forename: L
authors.initials: L
authors.lastname: Kittigul
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count / Q000187:drug effects; D002545:Brain Ischemia / Q000150:complications*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D011464:Epoprostenol / Q000097:blood; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013988:Ticlopidine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011464:Epoprostenol; D013988:Ticlopidine